title: Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012).
abstract: We report the results of 8 years (2005-2012) of the Daptomycin Surveillance Programme Worldwide. Consecutive non-duplicate bacterial isolates (prevalence design) were collected from patients with documented infections in 410 medical centres and were susceptibility tested by reference broth microdilution methods. A total of 164457 Gram-positive isolates were evaluated, including 97542 Staphylococcus aureus, 21413 coagulase-negative staphylococci (CoNS), 29619 enterococci and 15883 β-haemolytic streptococci. The prevalence of daptomycin-non-susceptible isolates was extremely low for all species in all geographic regions. Overall, the highest occurrence of non-susceptible isolates was observed among CoNS (0.19%), followed by Enterococcus faecium (0.18%), S. aureus (0.05%), Enterococcus faecalis (0.02%) and β-haemolytic streptococci (0.00%). Moreover, no trend towards increased daptomycin resistance (non-susceptibility) was observed for any species in any geographic region during the study interval. Against S. aureus, the daptomycin MIC(50/90) was 0.25/0.5 mg/L in all geographic regions (99.95% susceptible overall). Only 53 daptomycin-non-susceptible S. aureus isolates were observed and the vast majority (49; 92.5%) had a daptomycin MIC value only 1 log(2) dilution above the published susceptible breakpoint. Daptomycin was also active against CoNS (MIC(50/90), 0.25/0.5 mg/L; 99.81% susceptible), E. faecalis (MIC(50/90), 1/2 mg/L; 99.98% susceptible), E. faecium (MIC(50/90), 2/4 mg/L; 99.82% susceptible) including vancomycin-non-susceptible isolates (4521 isolates; MIC(50/90), 2/2 mg/L; 99.76% susceptible), and β-haemolytic streptococci (MIC(50/90), ≤0.06/0.25 mg/L; 100.0% susceptible). In conclusion, daptomycin has remained very active against indicated species worldwide, and no significant year-to-year or regional variation in daptomycin activity has been detected.
authors.affiliation: JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA. Electronic address: helio-sader@jmilabs.com.
authors.forename: Helio S
authors.initials: HS
authors.lastname: Sader
authors.affiliation: JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Farrell
authors.affiliation: JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA.
authors.forename: Robert K
authors.initials: RK
authors.lastname: Flamm
authors.affiliation: JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA.
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Jones
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017576:Daptomycin / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D062665:Epidemiological Monitoring; D014943:Global Health; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D016908:Gram-Positive Bacterial Infections / Q000453:epidemiology / Q000382:microbiology*; D006801:Humans; D007297:Inpatients; D008826:Microbial Sensitivity Tests; D015995:Prevalence
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin
keywords: Antimicrobial resistance; Bacteraemia; Gram-positive infections; Hospital-acquired infections